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Background The efficacy of statins, which are used
commonly in primary and secondary prevention of
cardiovascular diseases, shows a wide range of
interindividual variability. Genetic variants of OATP1B1, a
hepatic uptake transporter, can modify access of statins
to its therapeutic target, thereby potentially altering drug
efficacy. We studied the impact of genetic variants of
OATP1B1 on the lipid-lowering efficacy of statins in a
population-based setting.
Materials and methods The basis of the analysis was the
Study of Health in Pomerania, a cohort of 2732 men and
women aged 20–81 years. Included in the statistical
analysis to evaluate the impact of OATP1B1 on therapeutic
efficacy of statins were 214 individuals diagnosed with
dyslipidaemia during initial recruitment and receiving
statins during the 5-year follow-up.
Results Analysing the impact of the OATP1B1 genotype,
we observed a trend for lower statin-induced total
cholesterol reduction in carriers of the SLCO1B1 512C
variant. Restricting the analysis to patients receiving
simvastatin, pravastatin, lovastatin and fluvastatin indicated
a statistically significant association of the OATP1B1
genotype on lipid parameters at the 5-year follow-up. No
such effect was observed for atorvastatin. Calculation of
achievement of treatment goals according to the NCEP-
ATPIII guidelines showed a lower rate of successful
treatment when harbouring the mutant allele for patients
taking simvastatin (46.7 vs. 73.9%). A similar trend was
observed for pravastatin (34.4 vs. 70.4%).
Conclusion Genetic variants of OATP1B1 leading to
impaired hepatic uptake of statins translated into
reduced drug efficacy in a population-based cohort.
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Introduction
One class of drugs used commonly in the primary and
secondary prevention of atherosclerosis are statins.
Inhibition of the hepatic 3-hydroxymethyl-3-glutaryl
coenzyme A reductase (HMGCR) blocks endogenous
cholesterol synthesis and results in decreased cholesterol
levels, an effect driven mainly by upregulation of hepa-
tocellular low-density lipoprotein (LDL) receptors and
internalization of cholesterol-rich lipoproteins. With their
efficacy documented in a large number of clinical trials,
statins are prescribed chronically for millions of patients.
The lipid-lowering effects of statins, however, show
interindividual variability [1–3].
Thus, despite the widespread use of these drugs, pre-
diction of statin action in the individual patient remains a
challenge. Several studies analysing the influence of
genetic variants on the individual variability of statin
efficacy have focused on candidate genes obviously
involved in cholesterol metabolism and disease progres-
sion. These studies have focused on genes such as
the cholesterol receptors LDLR and SCARB1, the
cholesterol-metabolizing enzymes HMGCR and CYP7A1,
or the cholesterol transporter ABCG8 and ABCA1 [4–10].
In this report, we assessed the impact of a hepatic uptake
transporter as a promising pharmacokinetic candidate
gene on the efficacy of statins. It is now widely accepted
that the pharmacodynamics of statins – the inhibition of
the intracellular located HMGCR – depends in part on
processes facilitating the hepatocellular uptake of the
inhibitors. Hsiang et al. [11] reported that statins are
transported by the liver-enriched transporter OATP1B1,
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thereby identifying a mechanism modifying the cellular
uptake of statins. In 2001, Tirona et al. [12] identified
several polymorphisms localized in the coding region of
the gene to be associated with impaired transport func-
tion. In particular, the frequent single nucleotide poly-
morphism (SNP) SLCO1B1 c.521C results in significant
changes in pharmacokinetics (increased area under the
curve) of several statins (pravastatin, atorvastatin, rosu-
vastatin and simvastatin) in healthy volunteers (sum-
marized in the study of Niemi et al. [13]). The
assumption that OATP1B transporters are important in
pharmacokinetics of statins is indirectly supported by
findings showing that the frequently occurring function-
impairing allele SLCO1B1 c.521C is most predictive for
extrahepatic adverse events (myopathy, rhabdomyolysis)
of simvastatin therapy [14,15]. In detail, Link and col-
leagues had identified the noncoding rs4363657 poly-
morphism after performing a Genome-wide association
scan in patients experiencing simvastatin-induced myo-
pathy. The polymorphism identified is in almost com-
plete linkage disequilibrium with the function-impairing
allele SLCO1B1 c.521C (r2= 0.97). In addition, the
authors report findings from the HPS study, where LDL
reductions were 1.28 ± 0.25% smaller per copy of the
SLCO1B1 c.521C allele and 0.62 ± 0.18% larger per copy
of the SLCO1B1 c.388G allele. In a subsequent study,
Brunham and colleagues replicated the finding, reporting
an association of the rs4149056 (c.521C) variant with
simvastatin-associated myopathy [odds ratio (OR) of 3.2
(95% confidence interval 0.83–11.96)]. The relevance of
OATP1B1 SNPs for statin efficacy during chronic
application in a general population, however, is still
unclear. We therefore focused on the effect of SNPs
located in the coding sequence of OATP1B1 on the
therapeutic outcome of individuals treated with statins
from a well-characterized general population cohort.
Individuals recruited for a population-based study [Study
of Health in Pomerania (SHIP)] were evaluated for the
influence of impaired function alleles of OATP1B1 on
the efficacy of prescribed statins.
Taken together, we describe reduced efficacy of statin
treatment determined by the LDL-cholesterol-lowering
effects in individuals carrying functionally impaired var-
iants of OATP1B1. In addition, the fraction of individuals
reaching target levels was significantly reduced in this
subgroup. Importantly, although most of the statins
showed a similar trend in our population, no modulation
of efficacy by the genotype was detected in individuals
treated with atorvastatin.
Materials and methods
Study population
The presented data were derived from the population-
based SHIP. The study design and recruitment of the
study have been described previously in more detail [16].
In brief, a sample was drawn from the population aged
20–79 years of West Pomerania, a north-eastern coastal
region of Germany. From the 7006 initially sampled
individuals, 6265 were eligible for the study and 4308
participated (response 68.9%). Baseline examinations
(SHIP-0) were performed between 1997 and 2001.
Between 2002 and 2006, all participants were invited to a
follow-up examination (SHIP-1) and 3300 individuals
(1589 men), corresponding to a response rate of 83.5%
among living and eligible participants, participated. In
the present study, we included individuals who partici-
pated in the follow-up examination (N= 3300) and
excluded participants with missing values at baseline or
in the follow-up assessment for the polymorphisms
(n= 214) or for clinical data such as high-density lipo-
protein (HDL) (n= 39), LDL (n= 53), total cholesterol
(TC) (n= 30), triglycerides (TGs) (n= 30), HbA1c
(n= 30) or high-sensitive C-reactive protein (hs-CRP)
values (n= 216), respectively. In addition, we excluded
individuals taking glucocorticoids at baseline or at the
5-year follow-up (n= 84) or those with lack of information
on dosing of statins at follow-up (n= 18). Overall, we
excluded a total of 495 individuals. This number is
smaller than the sum of exclusions as there was an
overlap. The initial analytical sample included a total of
2805 participants; of these, only 214 individuals started a
statin therapy during the 5-year follow-up. All partici-
pants provided written informed consent. The study was
approved by the local Ethics Committee of the
University of Greifswald.
Data collection
All participants underwent an extensive standardized
medical examination including the collection of blood
samples. Waist circumference was measured to the
nearest 0.1 cm using an inelastic tape midway between
the lower rib margin and the iliac crest in the horizontal
plane, with the participant standing comfortably with
weight distributed evenly on both feet. The BMI was
calculated.
CHD risk assessment
The coronary heart disease (CHD) risk assessment was
performed using the Framingham Heart Score [17]. To
determine the individuals’ Framingham Heart Score,
data on age, sex, TC, cigarette smoking, measured HDL,
family history of premature CHD, CHD in female first-
degree relative below 65 years, systolic blood pressure
and antihypertensives (on the basis of the result of the
questionnaire; ATC code C02) were included as descri-
bed previously [17]. On the basis of the scores calculated,
treatment goals were determined according to ATPIII
[18]. In detail, the above-mentioned CHD risk factors of
age, smoking, systolic blood pressure and HDL levels
were assigned Framingham score points. Those points
are used to estimate a 10-year risk in men and women. In
the treatment guidelines ATPIII the 10-year risk has
been assigned to different categories, where individuals
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with CHD or CHD risk equivalents (10-year risk> 20%)
should reach an LDL-treatment goal below 100 mg/dl,
whereas those with more than two risk factors (10-year
risk< 20%) should reach levels below 130 mg/dl.
Individuals with only 0–1 risk factors (10-year risk< 10%)
should reach a treatment goal below 160 mg/dl. The
10-year risk was estimated for each individual separately;
then, the recommended LDL-treatment goal was com-
pared with the estimated cardiovascular disease risk in
SHIP-1. Those not reaching their treatment goal were
labelled the ‘failure’ group.
Medical examination and clinical chemical
measurements
A nonfasting venous blood sample was obtained from all
study participants between 07:00 a.m. and 04:00 p.m.
while sitting. Serum aliquots were stored at − 80°C. At
baseline, TC and HDL-cholesterol concentrations were
measured photometrically (Hitachi 704; Roche
Diagnostics, Mannheim, Germany), whereas follow-up
HDL concentrations were quantified by lipid electro-
phoresis (Helena SAS-3 system; Helena 7 BioSciences
Europe, Tyne and Wear, UK). To ensure comparability
in the longitudinal HDL analyses, we used baseline
HDL concentrations as the reference and calculated
corrected follow-up HDL-cholesterol concentrations on
the basis of a previously published conversion formula:
Corrected HDL=− 80+ (1.158× uncorrected HDL)
[19]. Doing so, we found that the average HDL-
cholesterol concentrations produced by the two meth-
ods were almost identical, suggesting that the differences
in HDL-cholesterol will be small within the range of
practical relevance. Serum LDL-cholesterol was mea-
sured by applying a precipitation procedure using dex-
tran sulphate (Immuno, Heidelberg, Germany) on an
Epos 5060 (Eppendorf, Hamburg, Germany). TG and
glucose concentrations were determined enzymatically
using reagents from Roche Diagnostics (Hitachi 717;
Roche Diagnostics). Glycated haemoglobin (HbA1c)
concentrations were determined by high-performance
liquid chromatography (Bio-Rad Diamat, Munich,
Germany). hs-CRP was determined immunologically on
a Behring Nephelometer II with commercially available
reagents from Dade Behring (Eschborn, Germany). All
assays were performed according to the manufacturers’
recommendations by skilled technical personnel. In
addition, the laboratory participates in official quarterly
German external proficiency testing programmes.
Dyslipoproteinaemia in SHIP-0 in individuals without
statin treatment (ATC code C10AA01–08) was deter-
mined on the basis of the blood work; the limits were as
follows: TG levels≥ 160 mg/dl (equivalent to
≥ 1.8 mmol/l), TC≥ 190 mg/dl (or > 5.0 mmol/l), LDL-
cholesterol> 150 mg/dl (or > 3.88 mmol/l), HDL-
cholesterol< 40 mg/dl (or < 0.9 mmol/l) in men and
HDL-cholesterol< 50 mg/dl (or < 1.1 mmol/l) in women.
Genotyping
All individuals included in the study were genotyped for
the frequently occurring nonsynonymous polymorphisms
SLCO1B1 c.521T>C and SLCO1B1 c.388A>G [12,13].
Assessment for the c.SLCO1B1 388A>G was performed
using a predeveloped TaqMan SNP detection assay
from Applied Biosystems (Darmstadt, Germany). Briefly,
reactions were carried out in a volume of 10 μl containing
5 μl Genotyping Master Mix (Applied Biosystems) 1 μl
genomic DNA and 0.5 μl of the Primer Probe-Mix.
Fluorescence was assessed using the Fast Real-Time
PCR system 7900 HT (Applied Biosystems) and the
Sequence Detection Software SDS 2.3 (Applied
Biosystems). The rs4149056 (c.SLCO1B1 521T>C)
polymorphism was detected in a genome-wide SNP scan
performed using the Affymetrix Human SNP Array
6.0 (Affymetrix Inc., Santa Clara, California, USA)
(SNP_A-860113) [20]. Data on SNP_A-860113 were
extracted and used for statistical analysis.
Statistical analysis
Categorical data were expressed as percentages; con-
tinuous data were expressed as arithmetic means (SDs).
Geometric means were reported for HbA1c and hs-CRP
as they followed an approximately log-normal distribu-
tion. Linear regression models were used for continuous
data. ORs for incident statin therapy, adjusted for age and
sex, were derived from logistic regression models. The
association between SNPs and baseline lipid parameters
was measured using linear regression adjusted for age and
sex. The association between SNPs and change in lipid
parameters was investigated using linear regression
models that were adjusted for statin dose and baseline
value of the lipid parameter comparing the group of
individuals harbouring the wild type with the group of
individuals harbouring at least one genetic variant allele.
For subgroups combining individuals treated with dif-
ferent statins, the simvastatin equipotent dose is used
instead of the actual statin dose. The equipotent doses
have been calculated as described by Helfand et al. [21].
Furthermore, the χ2-test was used to test the association
of categorical variables. Similarly, we related genetic
variants with achievement of ATPIII treatment goals
using binary logistic regression models that were adjusted
for statin dose. The statin doses used for statistical ana-
lysis were transformed into simvastatin equivalent doses
as described elsewhere [21]. P-values less than 0.05 were
considered statistically significant. All statistical calcula-
tions were carried out using Stata 12.1 (Stata Corp.,
College Station, Texas, USA).
Results
Dyslipoproteinaemia in untreated individuals in SHIP-0
Although evaluation of lipid parameters (TG, TC and
LDL-cholesterol) obtained during baseline examinations
(N= 2805) showed a total of 2048 individuals (81.51%)
of the SHIP-0 population, excluding those receiving
10 Pharmacogenetics and Genomics 2015, Vol 25 No 1
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statins during SHIP-0 (N= 179) to have dyslipoprotei-
naemia according to the definition by the National
Cholesterol Education Program ATPIII Guidelines, only
214 (10.45%) of these individuals received statins in
SHIP-1. Among those with dyslipoproteinaemia diag-
nosed by their blood work during the first recruitment,
male participants, despite similar ages and BMIs, had
higher HbA1c levels and reduced levels of hs-CRP
(Supplemental Table 1, Supplemental digital content 1,
http://links.lww.com/FPC/A783). The subpopulation of
individuals with dyslipoproteinaemia was further divided
into several subgroups according to their observed lipid
profile. Those subgroups summarized patients with iso-
lated hypertriglyceridaemia (only TG elevated), isolated
hypercholesterolaemia (LDL-cholesterol or LDL-
cholesterol and TC elevated), pandyslipoproteinaemia
(TG and LDL-cholesterol and TC elevated) and isolated
hypo-HDL-aemia (only HDL-cholesterol reduced). As
shown in Fig. 1, in this population, female participants
appeared more likely to have isolated hypercholester-
olaemia, whereas male participants appeared more likely
to have pandyslipoproteinaemia with elevation of TGs
and cholesterol. There is one important limitation in the
above-mentioned analysis, which needs to be highlighted
at this point. The quantification of lipid parameters was
not performed in a standardized fasting state. However,
by using the nonfasting blood values, we underestimated
the prevalence of hypercholesterolaemia [26% overall,
31% for individuals fasting (= not eating) for at least 7 h],
whereas hypertriglyceridaemia was overestimated (40%
overall vs. 29% for individuals fasting for at least 7 h).
This yields a biased estimation of dyslipoproteinaemia.
Association of the OATP1B1 genotype and lipid
parameters in treatment-naïve individuals in SHIP-0
It had been suggested before that genetic variants of
OATP1B1 are associated with increased endogenous
cholesterol synthesis [22]. We determined the influence
of OATP1B1 variants on nonfasting lipid parameters in
the subpopulation with dyslipoproteinaemia according to
the ATPIII guidelines [18]. Importantly, there was no
difference in the c.521C allele frequency (0.17) in this
subgroup compared with previously published fre-
quencies in a White population (0.14) [23] or the fre-
quency in the rest of the SHIP population. Similarly, the
frequency of the 388G allele was comparable to those
reported previously (0.39 compared with published 0.30)
[23]. At baseline, there was no association of the
SLCO1B1 c.521T>C genotype with LDL or TC plasma
levels, respectively, either in patients with isolated
hypercholesterolaemia (mean ±SD LDL-cholesterol,
SLCO1B1 c.521TT 3.97 ± 0.03, n= 795; TC 3.90 ± 0.03,
n= 340; CC 3.85 ± 0.13, n= 26, P= 0.514; mean TC c.
SLCO1B1 521TT 6.12 ± 0.03, TC 6.05 ± 0.04, CC
5.94 ± 0.14, P= 0.453) or in patients with pandyslipopro-
teinaemia [mean ± SD LDL-cholesterol, SLCO1B1
c.521TT 4.08 ± 0.03, n= 614; TC 4.17 ± 0.06, n= 243; CC
4.20 ± 0.22, n= 23 analysis of variance (ANOVA)
P= 0.457; mean ± SD TC c.SLCO1B1 521TT 6.47 ± 0.04;
TC 6.65 ± 0.06; CC 6.66 ± 0.21, P= 0.113]. Similarly,
assessment for the 388A>G variant did not indicate any
association of pathological lipid profiles with the geno-
type of the hepatic uptake transporter.
Lipid parameters in patients diagnosed with
dyslipoproteinaemia in SHIP-0 and treated with statins
in SHIP-1
As mentioned before, a total of 214 individuals were
summarized in the statin therapy group for statistical
analysis (Fig. 2, inset). These individuals had been
diagnosed with dyslipoproteinaemia in SHIP-0 on
the basis of the determination of lipid parameters
and received statin therapy until the re-examination
in SHIP-1. Importantly, the c.SLCO1B1 521T>C var-
iants did not influence the levels of LDL-cholesterol
cholesterol (ANOVA P= 0.871, Fig. 2a) or of TC
(P= 0.861, Fig. 2b) at the baseline examination.
We observed, however, a trend towards lower levels of
Fig. 1
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LDL-cholesterol in heterozygote carriers of the
SLCO1B1 c.388A>G polymorphism (P= 0.09, Fig. 2c).
Similar results were obtained for the TC plasma levels
at baseline in individuals harbouring the c.SLCO1B1
388AG genotype (P= 0.033, Fig. 2d). However, it seems
noteworthy that 5% lower TC levels as observed in
Fig. 2
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individuals are assumed to be of limited clinical sig-
nificance. Second, there is no gene–dose effect, sug-
gesting that this result is not directly associated with the
SLCO1B1 genotype. The impact of the previously
reported OATP1B1 haplotypes including the
SLCO1B1*1b (c.388G, c.521T), SLCO1B1*15 (388G,
521C) and SLCO1B1*5 (388A, 521C) variants was
determined. Individuals harbouring at least one mutation
in positions 388 and 521, respectively, were summarized
in the SLCO1B1*15 group (n= 63), whereas
SLCO1B1*1b (n= 86) represents individuals carrying at
least one mutation at position 388 and a homozygous
wild-type allele in position 521. Thus, SLCO1B1*5
(n= 6) summarizes individuals carrying at least one
mutated allele in position 521 and a homozygous wild-
type allele at 388. The baseline LDL-cholesterol levels
detected were statistically significantly lower in indivi-
duals harbouring the SLCO1B1*1b variant compared with
those carrying the SLCO1B1*1a genotype (Table 1). In
the following, the statistical analyses have to be adjusted
for baseline levels.
Association of OATP1B1 polymorphisms and changes in
lipid parameters
Interestingly, dyslipoproteinaemia in SHIP-0 led to an
initiation of antilipidaemic drug therapy in the 5-year
follow-up period in only 10.5% of the cases. In SHIP-1,
8.7 or 14.0% of the individuals had isolated hypercho-
lesterolaemia or pandyslipoproteinaemia, respectively,
and therefore indications for statin therapy were treated.
Despite this low figure of statin-treated patients, high
LDL-cholesterol at baseline was related to initiating a
statin therapy in the 5-year follow-up period [OR for
incident statin therapy= 3.04 (1.90; 4.85)]. In contrast,
elevated TG, TC and lowered HDL-cholesterol levels
were not significantly associated with statin use.
Testing the influence of SNPs on the efficacy of statins
in general, by comparing the per cent change in LDL-
cholesterol and TC levels, indicated a tendency towards
lower efficacy of statins for LDL-cholesterol (ANOVA
P= 0.082, Fig. 3a) and TC (ANOVA P= 0.035, Fig. 3b)
plasma level reduction in individuals harbouring the
521C variant, respectively (Fig. 3). Similar results were
obtained for the SLCO1B1 c.388A>G variant, where a
tendency for reduced LDL-lowering (ANOVA P= 0.033,
Fig. 3c) and TC-lowering (ANOVA P= 0.252, Fig. 3d)
efficacy associated with the SLCO1B1 c.388G allele was
observed. The statistical analysis was adjusted for base-
line lipid levels and statin doses; for this, the simvastatin
equipotent doses were calculated as described previously
by Helfand et al. [21].
However, even if statins are well-known substrates of the
hepatic OATP1B1 transporter, individual statins differ in
their affinity to this particular uptake transporter. To
elucidate the impact of OATP1B1 on individual statins,
the statin therapy group was stratified according to the
compound used in therapy. Most of the individuals in the
population studied here were treated with simvastatin
(50.9%, n= 110), followed by pravastatin (18.5%, n= 40)
and atorvastatin (18.0%, n= 39) (compare Tables 2 and
3). As shown in Table 2, there was no statistically sig-
nificant effect of the SLCO1B1 c.521T>C genotype on
LDL-lowering and TC-lowering efficacy of particular
statins. Similar results were obtained on testing the
influence of the SLCO1B1 c.388G>A genotype on
LDL-lowering and TC-lowering efficacy. However, it
appears that individuals harbouring the c.521C allele
showed a tendency towards an impaired efficacy of sta-
tins, whereas a trend towards higher efficacy of atorvas-
tatin was observed in individuals receiving this particular
statin. Importantly, there was no difference in dosing. It
appears that the efficacy of atorvastatin is different from
that of other statins. Assessment of all other statins
together showed a significant effect of the genotype on
statin efficacy (compare Tables 2 and 3). For further
analyses, patients treated with simvastatin, pravastatin
and atorvastatin are considered separately.
SLCO1B1 genotype on meeting the target LDL levels
Following the recommendations of the NCEP-ATPIII
guidelines [18], statin treatment goals depend on the risk
of CHD, which is determined in the Framingham CHD
risk assessment. Inclusion of this individual risk in the
analysis on the impact of OATP1B1 variants on the statin
efficacy showed that patients treated with simvastatin or
pravastatin and harbouring the SLCO1B1 521C allele
were less likely to achieve the treatment goal at the
5-year follow-up (Fig. 4). This was statistically significant
for individuals harbouring the 521C allele and receiving
simvastatin in particular (χ2-test; P= 0.02). There was no
such effect on atorvastatin efficacy (% of individuals
reaching the treatment goal c.SLCO1B1 521TT 69.9% vs.
Table 1 Haplotype analysis on baseline levels of lipid parameters in patients diagnosed with dyslipoproteinaemia according to the definition
by the American Society of Cardiology that started treatment with statins until the recruitment in SHIP-1 (data were analysed using a linear
regression model)
Haplotypes n Triglycerides (mmol/l) P-value LDL-cholesterol (mmol/l) P-value Total cholesterol (mmol/l) P-value HDL/LDL-ratio P-value
SLCO1B1*1a 64 2.06 ±0.17 – 4.89 ±0.14 – 7.08 ± 0.15 – 0.297 ± 0.012 –
SLCO1B1*1b 84 2.31 ±0.14 0.264 4.44 ±0.12 0.023 6.65 ± 0.13 0.043 0.316 ± 0.011 0.283
SLCO1B1*15 60 2.25 ±0.17 0.442 4.68 ±0.14 0.319 6.92 ± 0.16 0.477 0.307 ± 0.013 0.619
SLCO1B1*5 6 1.55 ±0.55 0.382 4.12 ±0.46 0.119 6.24 ± 0.51 0.120 0.334 ± 0.041 0.410
HDL, high-density lipoprotein; LDL, low-density lipoprotein; SHIP, Study of Health in Pomerania.
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c.SLCO1B1 521TC and CC 86.6%, χ2-test; P= 0.212).
Similarly, no effect on reaching treatment goals was
observed when testing the association with the SLCO1B1
388 genotype.
Discussion
The genetic contribution towards variation in the lipid-
lowering response to statin therapy has been the focus of
several studies [5,24–27]. Even though hepatic uptake
transporters, particularly OATP1B1, have been studied
extensively for their implication in hepatocellular
accumulation of substrate drugs showing a significant
influence of function-impairing polymorphisms on phar-
macokinetic parameters, studies focusing on the role of
those transporters in governing pharmacodynamics are
still limited. In the present report, we used a population-
based cohort study to evaluate the impact of function-
impairing polymorphisms on the real-life outcome of
statin therapy. In detail, we report that OATP1B1, par-
ticularly the 521T>C polymorphism, results in a trend
towards lower drug efficacy as indicated by the changes
in both LDL and TC levels (Fig. 3). In accordance with
the assumption of lower efficacy because of limited
hepatic uptake were findings on OATP1B1 functioning
as a determinant of successful statin therapy assessed to
determine the likelihood of achieving treatment goals
according to the NCEP-ATPIII guidelines (Fig. 4). As
mentioned before, statin therapy is accepted widely as an
important strategy to reduce cardiovascular incidences;
assuming that the OATP1B1 genotype is predictive for
the efficacy of this treatment would suggest that geno-
typing before starting treatment could be a useful tool to
stratify patients at risk.
Surprisingly, our data indicate that patients treated with
atorvastatin, even if characterized as a substrate of
OATP1B1 [28,29], did not show a predictive value of the
SLCO1B1 genotype on drug efficacy or treatment out-
come. This is in accordance with the findings obtained by
Thompson et al. [6], who carried out a genome-wide
association study that sought markers predictive for
LDL-cholesterol reduction in a population summarizing
Table 2 Association of the SLCO1B1 521T>C and mean change in
LDL cholesterol or TC for particular statins
c.SLCO1B1 521TT c.SLCO1B1 521TC and CC
n Mean change n Mean change P-value
ΔLDL cholesterol (mmol/l)
Simvastatin 77 −1.78 ±0.07 30 −1.64 ±0.11 0.295
Lovastatin 2 −0.50 2 −0.81 −
Pravastatin 28 −1.48 ±0.12 12 −0.87 ±0.19 0.011
Fluvastatin 14 −1.28 ±0.20 8 −0.82 ±0.28 0.243
All abovea 121 −1.66 ±0.06 52 −1.33 ±0.09 0.010
Atorvastatin 27 −1.88 ±0.13 14 −2.28 ±0.19 0.104
ΔTotal cholesterol (mmol/l)
Simvastatin 77 −2.13 ±0.08 30 −1.87 ±0.13 0.119
Lovastatin 2 −1.29 2 −1.08 −
Pravastatin 28 −1.57 ±0.20 12 −1.00 ±0.30 0.134
Fluvastatin 14 −1.28 ±0.24 8 −1.09 ±0.33 0.680
All abovea 121 −1.88 ±0.08 52 −1.52 ±0.12 0.013
Atorvastatin 27 −2.19 ±0.17 14 −2.36 ±0.24 0.580
Change in LDL cholesterol (%)
Simvastatin 77 −37.0 ±1.56 30 −33.6 ±2.5 0.249
Lovastatin 2 −16.07 2 −18.46 −
Pravastatin 28 −31.6 ±3.6 12 −15.6 ±5.5 0.022
Fluvastatin 14 −26.7 ±4.4 8 −18.2 ±6.2 0.324
All abovea 121 −34.1 ±1.4 52 −26.8 ±2.2 0.077
Atorvastatin 27 −36.3 ±2.8 14 −43.7 ±3.9 0.134
Change in total cholesterol (%)
Simvastatin 77 −30.0 ±1.3 30 −26.4 ±2.0 0.148
Lovastatin 2 −22.6 2 −17.0 −
Pravastatin 28 −22.4 ±3.8 12 −10.9 ±5.9 0.116
Fluvastatin 14 −18.3 ±3.5 8 −16.0 ±4.8 0.730
All abovea 121 −26.8 ±1.3 52 −20.7 ±2.0 0.012
Atorvastatin 27 −30.2 ±2.2 14 −32.2 ±3.1 0.612
Statin dose (mg)
Simvastatin 77 23.1 ±1.3 30 23.6 ±2.1 0.826
Lovastatin 2 15.7 2 14.2 −
Pravastatin 28 19.7 ±2.2 12 24.6 ±3.4 0.252
Fluvastatin 14 65.1 ±5.6 8 40.9 ±7.6 0.022
All abovea 121 54.0 ±6.8 52 52.6 ±10.4 0.911
Atorvastatin 27 17.8 ±1.9 14 16.6 ±2.6 0.717
Mean changes were derived from linear regression models adjusted for statin
dose and baseline values.
LDL, low-density lipoprotein; TC, total cholesterol.
aFor analysis of the summarized statin group, the simvastatin equipotent dose
was used.
Table 3 Association of the SLCO1B1 388A>G and mean change
in LDL cholesterol or TC for particular statins
c.SLCO1B1 388AA c.SLCO1B1 388AG and GG
n Mean change n Mean change P-value
ΔLDL cholesterol (mmol/l)
Simvastatin 41 −1.78 ±0.09 66 −1.71 ±0.07 0.539
Lovastatin 0 – 4 −0.65 ±0.15 −
Pravastatin 10 −1.59 ±0.22 30 −1.20 ±0.12 0.129
Fluvastatin 5 −1.21 ±0.34 17 1.08 ±0.17 0.747
All abovea 56 −1.68 ±0.09 117 −1.46 ±0.06 0.044
Atorvastatin 14 −2.17 ±0.19 27 −1.94 ±0.14 0.346
ΔTotal cholesterol (mmol/l)
Simvastatin 41 −2.09 ±0.11 66 −2.03 ±0.09 0.690
Lovastatin 0 – 4 −1.19 ±0.09 −
Pravastatin 10 −1.23 ±0.34 30 −1.45 ±0.19 0.579
Fluvastatin 5 −1.00 ±0.39 17 −1.27 ±0.20 0.566
All abovea 56 −1.85 ±0.11 117 −1.74 ±0.08 0.449
Atorvastatin 14 −2.49 ±0.23 27 −2.12 ±0.16 0.207
Change in LDL cholesterol (%)
Simvastatin 41 −36.3 ±2.1 66 −35.9 ±1.7 0.870
Lovastatin 0 – 4 −17.26 ±1.1 –
Pravastatin 10 −33.9 ±6.4 30 −24.5 ±3.6 0.213
Fluvastatin 5 −27.7 ±7.5 17 −22.4 ±3.8 0.550
All abovea 56 −35.0 ±2.2 117 −30.4 ±1.5 0.092
Atorvastatin 14 −43.6 ±3.9 27 −36.3 ±2.8 0.141
Change in total cholesterol (%)
Simvastatin 41 −28.8 ±1.8 66 −29.1 ±1.4 0.913
Lovastatin 0 – 4 −19.8 ±2.5 –
Pravastatin 10 −16.7 ±6.7 30 −19.7 ±3.8 0.707
Fluvastatin 5 −16.0 ±5.7 17 −17.9 ±3.0 0.790
All abovea 56 −25.9 ±2.0 117 −24.5 ±1.3 0.587
Atorvastatin 14 −35.6 ±3.0 27 −28.4 ±2.1 0.064
Statin dose (mg)
Simvastatin 41 23.8 ±1.8 66 22.8 ±1.4 0.673
Lovastatin 0 – 4 15.0 –
Pravastatin 10 17.8 ±3.8 30 22.3 ±2.2 0.313
Fluvastatin 5 72.1 ±9.9 17 51.7 ±5.3 0.087
All abovea 56 49.4 ±10.0 117 55.5 ±6.9 0.622
Atorvastatin 14 17.1 ±2.6 27 17.5 ±1.9 0.890
Mean changes were derived from linear regression models adjusted for statin
dose and baseline values.
LDL, low-density lipoprotein; TC, total cholesterol.
aFor analysis of the summarized statin group, the simvastatin equipotent dose
was used.
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genetic information of 5745 patients treated with ator-
vastatin. Testing candidate gene polymorphisms in
another cohort, they provided evidence that OATP1B1
polymorphisms might be associated with an increase in
HDL in patients treated with fluvastatin, whereas no
association was observed in patients treated with ator-
vastatin [30]. Similarly, Fu et al. [31] reported no sig-
nificant effect on atorvastatin efficacy in a Chinese
population. In agreement with this are findings showing
that genetic variants of OATP1B1 are not predictive for
atorvastatin-associated myopathic side effects [15]. It
should be noted at this point that in healthy volunteers,
the OATP1B1 polymorphisms exerted a more pro-
nounced effect on pharmacokinetic parameters of the
atorvastatin acid levels compared with the less lipophilic
rosuvastatin [32]. In addition, Lau et al. [33] suggested
Fig. 4
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that even if elimination of atorvastatin is governed by
multiple mechanisms including CYP enzymes and
efflux-mediating ABC transporters, the hepatic uptake
transporter might be the limiting factor in pharmacoki-
netics. Recently, a genetic variant of the efflux trans-
porter ABCG2 has been identified to be associated with
the LDL-reducing efficacy of rosuvastatin performing a
Genome-wide association scan [34]. In general, despite
being summarized in one compound class, statins differ
markedly in their pharmacokinetics. Indeed, the more
lipophilic compounds such as the simvastatin, atorvasta-
tin and lovastatin studied here are mainly metabolized by
cytochrome P450 (CYP) 3A, whereas pravastatin is
excreted mostly unchanged. In addition, statins differ in
their affinity (determined as Km value in vitro) to the
OATP1B1 transporter, with the following values deter-
mined in vitro for the particular statin 12.4 μmol/l
for atorvastatin [11,28,33], 1.4–3.5 μmol/l for fluvastatin
[35,36] and 14–34 μmol/l for the less lipophilic pravastatin
[11,37,38].
For pravastatin, several studies have focused on the
impact of the genetic makeup of the uptake transporter
on the efficacy. Tachibana-Iimori et al. [39] explored
retrospectively the efficacy of atorvastatin, pravastatin
and simvastatin, showing attenuated response of statins
in terms of TC reduction. Similarly, Zhang et al. [40]
found an effect of the genotype after 30 days of treatment
with pravastatin (20 mg/day). In contrast, Igel et al. [41]
could not find more than a weak trend after 21 days of
treatment with 40 mg pravastatin. Similarly, a lower
LDL-cholesterol response (−1.28% per allele) has been
reported for simvastatin by the SEARCH collaborative
group [14]. It has been suggested previously that the
SLCO1B1 genotype is only predictive of a slower
response to pravastatin treatment as genotype-associated
reduction in TC was only observed in the assessment
after 8 weeks, but not after a 1-year treatment [42].
Furthermore, a population-based survey showed an
influence of genetic variants in the efflux transporter
ABCB1 genotype on simvastatin efficacy in men by
showing that previously identified SNPs are associated
with larger reduction of lipid parameters than carriers of
the wild-type haplotype [43]. Similarly, Tomlinson et al.
[44] reported a significant effect of genetic variants of the
ABCG2 transporter in a patient cohort treated with
rosuvastatin. In summary, the present work confirms our
hypothesis of intrahepatic drug effects as assessed by
reaching treatment goals being dependent on the genetic
makeup of hepatocellular uptake transport. However,
one limitation of this study is that the duration of treat-
ment was not assessed. This should be included in future
population-based cohorts if pharmacogenomics analyses
have to be carried out. In addition, if accounting for
multiple testing as performed in this particular study to
cover various aspects of the relationship between
genotype and drug efficacy, the statistical significance of
the findings is no longer confirmed.
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